Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Cancer Insights

- PMLiVE

Celgene signs $3.3bn cancer deal with OncoMed

Includes lead candidate demcizumab

- PMLiVE

Nexavar cleared for thyroid cancer by FDA

Bayer and Onyx win expansion of oncology drug’s use in US

Removing the Roadblocks to Effective Patient Treatment

How can pharma benefit from improved patient understanding? Welcome to a new column in which Mary Assimakopoulos, Founding Director of pharma market research specialist the Research Partnership reveals findings from...

Research Partnership

Driving Earlier Diagnosis: A Case Study in Psoriatic Arthritis

Following a survey of 1000 Psoriatic Arthritis patients, Mary Assimakopoulos shares some of the root causes behind a late diagnosis of this debilitating illness, and the patients’ own feelings towards...

Research Partnership

The Difficulties of Living with Depression Don’t End with the Illness Itself

This month Mary Assimakopoulos examines some of the insights gathered while surveying 2,000 patients suffering with this often misunderstood mental illness.

Research Partnership

Patient Power: Too Much of a Good Thing?

Mary Assimakopoulos, reveals findings from the company’s Therapy Watch market research data, investigating patient behaviour in Crohn’s Disease and discusses how pharma can benefit from improved patient understanding

Research Partnership

- PMLiVE

GSK and Pfizer combine melanoma drugs in new trial

Will investigate effects of adding palbociclib to Mekinist

Roche - Basel

EU backs Roche’s Kadcyla in breast cancer

Green light for Herceptin follow-up

Bayer symbol

EU approval for Bayer’s prostate cancer drug

Xofigo wins marketing authorisation from European Commission

Roche - Basel

Roche cuts $1bn deal on cancer therapy with Immatics

Licenses series of early-stage oncology immunotherapy programmes

- PMLiVE

Havas’ UK Nurofen campaign to cost £3m

Reckitt Benckiser rolls out TV advertisements in time for flu and cold season

- PMLiVE

Late-stage ovarian cancer

Novel treatment strategies have yielded several promising agents that have reached phase III

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links